Fc-Modified Anti-CD19 Antibody for SLE Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for systemic lupus erythematosus (SLE) are non-specific and often have long-term safety concerns, with limited targeted therapies available, and existing anti-CD19 antibody therapies like obexelimab do not meet primary endpoints in clinical trials due to inefficacy in reducing inflammation and organ damage.
Innovation Solution
The use of a human anti-CD19 antibody with Fc modifications such as S267E and L328F, in combination with biomarkers like CD27, TCF7, CD40LG, FOXP3, CD28, APP, IL-3RA, and MAP1A to determine treatment efficacy and susceptibility, allowing for personalized therapy by identifying subjects with increased biomarker expression for effective antibody administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific immunosuppressants are used to treat SLE, then inflammation and organ damage are reduced, but long-term safety concerns arise including hypertension, diabetes, osteoporosis, and infection risk
Solution Approach 1:
The patent modifies the Fc region parameters of the anti-CD19 antibody by introducing specific amino acid substitutions (S267E, L328F) to enhance FcγRIIb binding affinity. This parameter change in the antibody structure enables more effective B-cell suppression with lower doses, reducing the harmful long-term effects of immunosuppression while maintaining disease control
Solution Approach 2:
The patent applies local quality by targeting specifically CD19-expressing B cells rather than using broad non-specific immunosuppressants. The Fc modifications are localized to enhance binding to FcγRIIb receptors on specific cell types, enabling precise therapeutic action that spares healthy tissues from the harmful effects of general immunosuppression
2Adaptability or versatility
If targeted anti-CD19 antibody therapy is developed, then treatment specificity is improved, but clinical trial endpoints were not met due to insufficient inflammation reduction
Solution Approach 1:
The patent creates a composite therapeutic molecule by combining the anti-CD19 antibody variable regions with a modified Fc region that has enhanced FcγRIIb binding properties. This composite structure integrates both the specificity of CD19 targeting and the enhanced effector function of FcγRIIb engagement, achieving both treatment specificity and reliable inflammation reduction
Solution Approach 2:
The patent changes the Fc region parameters by introducing amino acid substitutions that increase FcγRIIb binding affinity. This parameter modification enhances the antibody's ability to suppress B-cell activation and reduce inflammation, meeting the previously unmet clinical efficacy requirements while maintaining targeted specificity
3Adaptability or versatility
If only one new therapy (belimumab) has been approved in over 50 years, then treatment options are limited, but the need for more targeted agents with better safety profiles exists
Solution Approach 1:
The patent introduces novel Fc region parameter modifications (S267E, L328F substitutions) that differentiate this anti-CD19 antibody from existing therapies like belimumab. These parameter changes create a new therapeutic class with improved safety parameters by targeting B cells more specifically and reversibly, expanding treatment options with a superior safety profile
Solution Approach 2:
The patent segments the therapeutic approach by separating the targeting function (anti-CD19) from the effector function (FcγRIIb binding). This segmentation allows for optimized design where the Fc region can be independently modified to enhance safety and efficacy, creating a new treatment option distinct from existing therapies
Data Source
AI summary
The disclosure relates to methods of detecting one or more biomarkers. and/or treating autoimmune diseases such as systemic lupus erythematous (SLE) with an anti-CD19 antibody based on the presence of such biomarkers. The biomarkers can be separate or in combination, and their detection can be used in multiple different methods.